Literature DB >> 12119140

Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3.

M E R Hamdy1, S M El-Gibaly, A M Montasser.   

Abstract

BALB/c mice were immunized with live rough Brucella abortus RB51 or smooth Brucella melitensis Rev. 1 vaccines and challenged with a B. melitensis field strain. Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice vaccinated with RB51 gave negative results in the conventional serological tests prior to challenge, namely; standard tube agglutination test (SAT), Rose Bengal plate test (RBPT), buffered acidified plate antigen test (BAPAT), and mercaptoethanol test (MET). Sero-conversion took place to a whole-cell bacterial buffered RB51 antigen after vaccination and persisted for 7 weeks post-vaccination. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Protection units were showed that Rev. 1 vaccine was superior to RB51 vaccine in protection of mice against B. melitensis. However, RB51 vaccine has the advantage that it would not elicit antibodies to standard serological tests based on the LPS O antigen. RB51 vaccine could therefore be used for control of B. melitensis infection and avoid confusion in the use of standard sero-diagnostic tests.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119140     DOI: 10.1016/s0378-1135(02)00088-3

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  8 in total

1.  Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice.

Authors:  M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Brucella melitensis 16MΔTcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection.

Authors:  Zhiqiang Li; Junbo Zhang; K E Zhang; Qiang Fu; Zhen Wang; Tiansen Li; Hui Zhang; Fei Guo; Chuangfu Chen
Journal:  Exp Ther Med       Date:  2015-07-06       Impact factor: 2.447

3.  Protective properties of rifampin-resistant rough mutants of Brucella melitensis.

Authors:  R Adone; F Ciuchini; C Marianelli; M Tarantino; C Pistoia; G Marcon; P Petrucci; M Francia; G Riccardi; P Pasquali
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

4.  A potent Brucella abortus 2308 Δery live vaccine allows for the differentiation between natural and vaccinated infection.

Authors:  Junbo Zhang; Shuanghong Yin; Fei Guo; Ren Meng; Chuangfu Chen; Hui Zhang; Zhiqiang Li; Qiang Fu; Huijun Shi; Shengwei Hu; Wei Ni; Tiansen Li; Ke Zhang
Journal:  J Microbiol       Date:  2014-07-04       Impact factor: 3.422

5.  Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.

Authors:  D Monreal; M J Grilló; D González; C M Marín; M J De Miguel; I López-Goñi; J M Blasco; A Cloeckaert; I Moriyón
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

6.  A novel Omp25-binding peptide screened by phage display can inhibit Brucella abortus 2308 infection in vitro and in vivo.

Authors:  Junbo Zhang; Fei Guo; Xiaoqiang Huang; Chuangfu Chen; Ruitian Liu; Hui Zhang; Yuanzhi Wang; Shuanghong Yin; Zhiqiang Li
Journal:  J Med Microbiol       Date:  2014-04-10       Impact factor: 2.472

7.  Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.

Authors:  Mina J Izadjoo; Apurba K Bhattacharjee; Chrysanthi M Paranavitana; Ted L Hadfield; David L Hoover
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

8.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.